Codexis Sells its Hungarian Operations
News Mar 14, 2014
Codexis, Inc. today announced the sale of its subsidiary in Hungary to Intrexon Corporation. The transaction closed on March 13, 2014, with a purchase price of. No proprietary Codexis materials or intellectual property were included in the transaction.
“We are very pleased with this transaction,” said John Nicols, President and CEO of Codexis. “We were able to transfer our dedicated and talented employees in Hungary to Intrexon and to monetize one of our assets as part of the wind down of our biofuels business.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019